BofA cuts CRISPR Therapeutics stock price target to $83 on valuation

BofA Securities trimmed its price target on CRISPR Therapeutics to $83 from $86 while keeping a Buy rating, citing only minor changes after Q1 2026 results. The firm still sees Casgevy ramping commercially and values it at $25 per share, but adjusted its cash/share model after the March convertible issuance. The broader financing backdrop remains supportive, with CRISPR having raised $550 million in convertible senior notes due 2031 and pro forma cash estimated at $2.56 billion.

Analysis

The market is treating CRSP like a binary science story, but the more immediate driver is capital structure optionality. The heavier convertible raise lowers near-term dilution risk in the event of equity weakness, while also giving management a multi-quarter runway to wait for data rather than force commercialization decisions into a weak tape. That tends to support the multiple even if the pipeline is still a longer-dated call option.

The key second-order issue is that the stock is likely to trade less on Casgevy sell-through than on whether the company can prove a second monetizable asset before cash burn becomes the debate again. If the back half of 2026 readouts disappoint, the market will reprice CRSP from a platform company to a one-product balance sheet story, and the convert structure will start to matter because upside gets capped by the financing overhang. Conversely, even modest positive pipeline signals should have outsized valuation impact because the current enterprise value still appears anchored to cash and one commercial launch.

Consensus seems to be underestimating how much of the near-term upside is driven by duration extension, not operating momentum. The financing improves the odds that CRSP survives long enough to earn the optionality embedded in the pipeline, which is worth more in a rising biotech multiple environment than in a distressed one. The risk is that investors confuse balance-sheet strength with fundamental de-risking; if adoption metrics flatten, the stock can drift for months despite a strong cash position.

Key Decisions for Investors

• Maintain/accumulate CRSP on weakness over the next 2-6 weeks, with a medium-term target into 2H26 data. Risk/reward is attractive if the market continues to value the balance sheet plus pipeline optionality rather than just current revenue.
• For more convex exposure, buy CRSP call spreads targeting the 2H26 catalyst window rather than outright equity. This limits downside if commercialization stalls while preserving upside if early-stage data re-rates the platform.
• Pair trade: long CRSP vs. short a cash-burning, single-asset biotech with similar market cap but weaker balance sheet. The relative trade should benefit if investors reward financing durability and punish companies that must raise into uncertainty.
• If holding an existing long, hedge with a partial collar around the next two clinical update dates. The main risk is a multi-quarter drawdown if the pipeline remains unvalidated and the market refocuses on dilution arithmetic.